• Explore /
  • Poster
  • / Phase I trial of autologous CD19-targeted CAR-modified t cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL.

Phase I trial of autologous CD19-targeted CAR-modified t cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL.

Abstract Poster

Authors

null

Jae Hong Park

Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY

Jae Hong Park , Isabelle Riviere , Xiuyan Wang , Shirley Bartido , Michel Sadelain , Renier J. Brentjens

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Leukemia, Myelodysplasia, and Transplantation

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Leukemia

Clinical Trial Registration Number

NCT01416974

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 7020)

DOI

10.1200/jco.2014.32.15_suppl.7020

Abstract #

7020

Poster Bd #

12

Abstract Disclosures

Similar Posters

First Author: Mark Blaine Geyer

First Author: Marco L. Davila

First Author: Jennifer N. Brudno

First Author: Tanya B. Dorff